Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 181 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE
Year : 2011  |  Volume : 1  |  Issue : 2  |  Page : 97-103

Experimental model proposed to deduce pharmacological evidence of the beta-cell neogenesis activity of Argyrolobium roseum vis-a-vis an evaluation of its hypoglycemic activity


1 Departments of Pharmacology and Therapeutics, Acharya Shri Chander College of Medical Sciences and Hospital, Sidhra, Jammu, India
2 Department of Pathology, Acharya Shri Chander College of Medical Sciences and Hospital, Sidhra, Jammu, India
3 Department of Physiology, Acharya Shri Chander College of Medical Sciences and Hospital, Sidhra, Jammu, India

Correspondence Address:
O P Gupta
Department of Pharmacology and Therapeutics, Acharya Shri Chander College of Medical Sciences and Hospital, Sidhra, Jammu - 180 017
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-516X.91153

Rights and Permissions

Background: Argyrolobium roseum is described in texts for its botanical aspects with no mention of its therapeutic uses. Recently, a solvent fraction of this plant has been reported to possess insulin secretagogue activity. Objective: Primary objective of the study was to evaluate the hypoglycemic activity of different fractions of Argyrolobium roseum plant. Secondary objective was to devise a model for detecting its beta-cell neogenesis activity. Materials and Methods: Alcoholic fraction (AR) was studied in fasting, glucose-loaded and streptozotocin (STZ)-treated hyperglycemic rats. For deducing beta-cell neogenesis activity, a sub-lethal dose of STZ, causing delayed death in the animals, was administered. Results: AR in a dose of 200 mg/kg showed hypoglycemic activity in fasting and STZ-treated rats. With sub-lethal dose of STZ, recovery from hyperglycemia was seen. Conclusion: AR of Argyrolobium roseum possesses hypoglycemic and a possible beta-cell neogenesis activity. Further studies are required to confirm its beta-cell neogenesis potential by cytological methods and to establish its role in the treatment of type 2 diabetes.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3015    
    Printed139    
    Emailed2    
    PDF Downloaded357    
    Comments [Add]    

Recommend this journal